Our product portfolio features several leading products, including Rasuvo®, Metoject®, RUPALLTM, Gliolan®, and Treosulfan. Through our business development strategy, we are also actively licensing and/or acquiring new products to supplement our growing pipeline.
Gliolan is an orally administered drug used for the visualization of certain brain tumors.
Treosulfan is a conditioning agent used prior to stem cell transplantation.
Portfolio by Growth Phase
*Percentages are of the Company’s revenue as disclosed in the condensed interim consolidated statements of loss and comprehensive income (unaudited) of the Company for the three-month period ended June 30, 2019, as filed on SEDAR.
Two Robust Divisions
Our strong North American commercial platform is supported by our operations via our two divisions: Medexus Pharma Canada and Medexus Pharma USA.